RK

Ritesh Karnani

Active Director Director DIN 03178335
DIN 03178335 First appointment Nov 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 7 active board seats
Past companies 1 historical roles
Total affiliations 8 Since Nov 2011
Shareholding value •••• Premium profile

About Ritesh Karnani

Data last updated:

Ritesh Karnani is a Director at Synnat Pharma Private Limited (since 2022), Designated Partner at Rentexo Renting Services Llp (since 2024) and Designated Partner at Smnr Exim Llp (since 2024), and holds 4 more current directorships. The companies operate in Pharma, Financial Services and Business Services. The 4 current companies with reported revenue have a combined latest revenue of ₹76.79 Cr; the largest is Synnat Pharma Private Limited at ₹71.34 Cr (FY 2024). Earlier, Ritesh Karnani was a Director at Cudos Lifesciences Private Limited (2011–2024).

DIN 03178335
Primary Designation Director
Industry Pharma
First Appointment 24 Nov 2011
Oldest Company Age 34 yrs
Largest company Synnat Pharma Private Limited · ₹71.34 Cr (FY 2024)
Combined revenue ₹76.79 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Synnat Pharma Private Limited U24232TG2011PTC074746
Director03 Dec 20222011₹71.34 Cr (FY 2024)Active
Designated Partner06 Aug 20242016₹2.53 Cr (FY 2021)Active
Smnr Exim Llp AAD-5875
Designated Partner06 Aug 20242015₹1.59 Cr (FY 2023)Active
R G Credit Pvt Ltd U65992WB1992PTC056496
Director05 Sep 20221992₹1.34 Cr (FY 2024)Active
Designated Partner02 Jun 20262026Active
Designated Partner02 Jun 20262026Active
R G Credit Pvt Ltd U65992MH1992PTC472832
Director05 Sep 20221992Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cudos Lifesciences Private Limited U24290PN2010PTC135938
Director24 Nov 20112010₹91.9 Lakh (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Ritesh Karnani

Directorship timeline

Open interactive timeline →
Synnat Pharma Private Limited
Smnr Exim Llp
Rentexo Renting Services Llp
R G Credit Pvt Ltd
Premium access

Shareholding and investment profile for Ritesh Karnani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritesh Karnani

Ritesh Karnani currently holds 7 directorships: Synnat Pharma Private Limited (Director, since 03 Dec 2022, revenue ₹71.34 Cr (FY 2024)); Rentexo Renting Services Llp (Designated Partner, since 06 Aug 2024, revenue ₹2.53 Cr (FY 2021)); Smnr Exim Llp (Designated Partner, since 06 Aug 2024, revenue ₹1.59 Cr (FY 2023)); R G Credit Pvt Ltd (Director, since 05 Sep 2022, revenue ₹1.34 Cr (FY 2024)); Rentexo Hyderabad Llp (Designated Partner, since 02 Jun 2026); and 2 more.

Ritesh Karnani was first appointed on 24 Nov 2011 as Director at Cudos Lifesciences Private Limited. The most recent appointment on record is 02 Jun 2026 at Sankhrail Renting Services Llp.

The 4 current companies of Ritesh Karnani that report revenue have a combined latest revenue of ₹76.79 Cr: Synnat Pharma Private Limited ₹71.34 Cr (FY 2024); Rentexo Renting Services Llp ₹2.53 Cr (FY 2021); Smnr Exim Llp ₹1.59 Cr (FY 2023); R G Credit Pvt Ltd ₹1.34 Cr (FY 2024).

Ritesh Karnani held 1 earlier board appointment: Cudos Lifesciences Private Limited (Director, 24 Nov 2011 to 01 Nov 2024).

The current boards of Ritesh Karnani's companies include Ramesh Kumar Karnani (Synnat Pharma Private Limited), Siddharth Karnani (Synnat Pharma Private Limited), Vineet Bagri (Rentexo Hyderabad Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available